Hermine I. Brunner, MD, MSc
is a pediatric rheumatologist with a special clinical and research interest in pediatric lupus. Her research is focused on biomarker discovery and the testing of new medications for lupus. Dr. Brunner is also involved in trial design and provides statistical support at Cincinnati Children's and is pioneering the development of outcome measures and improving the quality of care for children with lupus and other rheumatic diseases. Visit the Brunner Lab.
513-636-4676
hermine.brunner@cchmc.org
Hermine I. Brunner, MD, MSc
Academic Information
Professor, UC Department of Pediatrics
Show All
Specialties
Clinical InterestsHealth-related quality of life; outcome research; lupus Research InterestsEconomic analyes; HRQOL; measurement development; outcome research; lupus Visit the Brunner Lab.
Biography
Hermine Brunner, MD, MSc, is a pediatric rheumatologist with a special clinical and research interest in pediatric lupus. Her research is focused on biomarker discovery and the testing of new medications for lupus. She is also involved in trial design and provides statistical support at Cincinnati Children's. As head of the Lupus Center, she is involved in the conduction of the Lupus Clinic and the organization of Lupus Support Groups. She also pioneers the development of outcome measures and improving the quality of clinical of children with lupus and other rheumatic diseases.
Education and Training
MD: Ludwig Maximilan University, Munich, Germany, 1991. Residency: University of Chicago, 1997. Fellowship: University of Toronto & Cincinnati, 1999. MSc: Clinical Epidemiology: University of Toronto, 1999. Certification: Pediatrics 1997; Rheumatology 2002.
Publications
View PubMed Publications
Sherwin CM, Fukuda T, Brunner HI, Goebel J, Vinks AA. The evolution of population pharmacokinetic models to describe the enterohepatic recycling of mycophenolic Acid in solid organ transplantation and autoimmune disease. Clin Pharmacokinet. 2011 Jan 1;50(1):1-24.
Sagcal-Gironella AC, Fukuda T, Wiers K, Cox S, Nelson S, Dina B, Sherwin CM, Klein-Gitelman MS, Vinks AA, Brunner HI. Pharmacokinetics and Pharmacodynamics of Mycophenolic Acid and Their Relation to Response to Therapy of Childhood-Onset Systemic Lupus Erythematosus. Semin Arthritis Rheum. 2010 Jul 22.
Brunner HI, Higgins GC, Klein-Gitelman MS, Lapidus SK, Olson JC, Onel K, Punaro M, Ying J, Giannini EH. Minimal clinically important differences of disease activity indices in childhood-onset systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2010 Jul;62(7):950-9.
Brunner HI, Klein-Gitelman MS, Higgins GC, Lapidus SK, Levy DM, Eberhard A, Singer N, Olson JC, Onel K, Punaro M, Schanberg L, von Scheven E, Ying J, Giannini EH. Toward the development of criteria for global flares in juvenile systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2010 Jun;62(6):811-20.
Brunner HI, Higgins GC, Wiers K, Lapidus SK, Olson JC, Onel K, Punaro M, Ying J, Klein-Gitelman MS, Giannini EH. Prospective validation of the provisional criteria for the evaluation of response to therapy in childhood-onset systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2010 Mar;62(3):335-44.
Mina R, Brunner HI. Pediatric lupus--are there differences in presentation, genetics, response to therapy, and damage accrual compared with adult lupus?Rheum Dis Clin North Am. 2010 Feb;36(1):53-80, vii-viii.
Ford KR, Myer GD, Melson PG, Darnell SC, Brunner HI, Hewett TE. Land-Jump Performance in Patients with Juvenile Idiopathic Arthritis (JIA): A Comparison to Matched Controls. Int J Rheumatol. 2009;2009:478526. Epub 2010 Jan 27.
Kocharla L, Taylor J, Weiler T, Ting TV, Luggen M, Brunner HI. Monitoring methotrexate toxicity in juvenile idiopathic arthritis. J Rheumatol. 2009 Dec;36(12):2813-8. Epub 2009 Nov 16.
Brunner HI, Ravelli A. Developing outcome measures for paediatric rheumatic diseases. Best Pract Res Clin Rheumatol. 2009 Oct;23(5):609-24. Review.
Hinze CH, Suzuki M, Klein-Gitelman M, Passo MH, Olson J, Singer NG, Haines KA, Onel K, O'Neil K, Silverman ED, Tucker L, Ying J, Devarajan P, Brunner HI. Neutrophil gelatinase-associated lipocalin is a predictor of the course of global and renal childhood-onset systemic lupus erythematosus disease activity. Arthritis Rheum. 2009 Sep;60(9):2772-81.
Grants
|
Edward H. Giannini, MSc, DrPH
serves as project director for numerous clinical trials, and has vested a considerable part of his research career in the methodological aspects of conducting clinical trials in children with rheumatic diseases. In 2003 he was awarded the Ohio River Valley Chapter of the Arthritis Foundation for Outstanding Contributions in Research of Behalf of Children with Arthritis.
513-636-7634
edward.giannini@cchmc.org
Edward H. Giannini, MSc, DrPH
Academic Information
Professor, UC Department of Pediatrics
Show All
Biography
Publications
View PubMed Publications
Lovell DJ, Passo MH, Beukelman T, Bowyer SL, Gottlieb BS, Henrickson M, Ilowite NT, Kimura Y, DeWitt EM, Segerman J, Stein LD, Taylor J, Vehe RK, Giannini EH. Measuring process of arthritis care: a proposed set of quality measures for the process of care in juvenile idiopathic arthritis. Arthritis Care Res (Hoboken). 2011 Jan;63(1):10-6. doi: 10.1002/acr.20348. Giannini EH, Ilowite NT, Lovell DJ, Wallace CA, Rabinovich CE, Reiff A, Higgins G, Gottlieb B, Chon Y, Zhang N, Baumgartner SW. Effects of long-term etanercept treatment on growth in children with selected categories of juvenile idiopathic arthritis. Arthritis Rheum. 2010 Nov;62(11):3259-64. doi: 10.1002/art.27682. Brunner HI, Higgins GC, Klein-Gitelman MS, Lapidus SK, Olson JC, Onel K, Punaro M, Ying J, Giannini EH. Minimal clinically important differences of disease activity indices in childhood-onset systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2010 Jul;62(7):950-9. Brunner HI, Klein-Gitelman MS, Higgins GC, Lapidus SK, Levy DM, Eberhard A, Singer N, Olson JC, Onel K, Punaro M, Schanberg L, von Scheven E, Ying J, Giannini EH. Toward the development of criteria for global flares in juvenile systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2010 Jun;62(6):811-20. Brunner HI, Higgins GC, Wiers K, Lapidus SK, Olson JC, Onel K, Punaro M, Ying J, Klein-Gitelman MS, Giannini EH. Prospective validation of the provisional criteria for the evaluation of response to therapy in childhood-onset systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2010 Mar;62(3):335-44. Giannini EH, Mehta AB, Hilz MJ, Beck M, Bichet DG, Brady RO, West M, Germain DP, Wanner C, Waldek S, Clarke JT, Mengel E, Strotmann JM, Warnock DG, Linhart A. A validated disease severity scoring system for Fabry disease. Mol Genet Metab. 2010 Mar;99(3):283-90. Giannini EH, Ilowite NT, Lovell DJ, Wallace CA, Rabinovich CE, Reiff A, Higgins G, Gottlieb B, Singer NG, Chon Y, Lin SL, Baumgartner SW; Pediatric Rheumatology Collaborative Study Group. Long-term safety and effectiveness of etanercept in children with selected categories of juvenile idiopathic arthritis. Arthritis Rheum. 2009 Sep;60(9):2794-804. Carrasco R, Lovell DJ, Giannini EH, Henderson CJ, Huang B, Kramer S, Ranz J, Heubi J, Glass D. Biochemical markers of bone turnover associated with calcium supplementation in children with juvenile rheumatoid arthritis: results of a double-blind, placebo-controlled intervention trial. Arthritis Rheum. 2008 Dec;58(12):3932-40. Lovell DJ, Ruperto N, Goodman S, Reiff A, Jung L, Jarosova K, Nemcova D, Mouy R, Sandborg C, Bohnsack J, Elewaut D, Foeldvari I, Gerloni V, Rovensky J, Minden K, Vehe RK, Weiner LW, Horneff G, Huppertz HI, Olson NY, Medich JR, Carcereri-De-Prati R, McIlraith MJ, Giannini EH, Martini A; Pediatric Rheumatology Collaborative Study Group; Pediatric Rheumatology International Trials Organisation. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med. 2008 Aug 21;359(8):810-20. Lovell DJ, Reiff A, Ilowite NT, Wallace CA, Chon Y, Lin SL, Baumgartner SW, Giannini EH; Pediatric Rheumatology Collaborative Study Group. Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum. 2008 May;58(5):1496-504.
Grants
|
David N. Glass, MD
Professor of Pediatrics
has long standing interests in basic and translational research to better understand the molecular mechanisms responsible for disease risk and severity in Juvenile Idiopathic Arthritis (JIA). Dr. Glass is the former Associate Director, Cincinnati Children's Research Foundation. Visit the Glass/Thompson Lab.
513-636-7686
david.glass@cchmc.org
David N. Glass, MD
Professor of Pediatrics
Academic Information
Professor, UC Department of Pediatrics
Show All
Specialties
Biography
Education and Training
MD: University of Birmingham, England, 1965.
Residency: Internal Medicine, Charing Cross Hospital, London, England.
Fellowship: Rheumatology, Kennedy Institute of Rheumatology, London, England; Charing Cross Hospital, London, England; Robert B. Brigham Hospital, Harvard Medical School, Boston, MA.
Certification: Internal Medicine, Royal College of Physicians, London, England, 1968.
Publications
View PubMed Publications
Thompson SD, Sudman M, Ramos PS, Marion MC, Ryan M, Tsoras M, Weiler T, Wagner M, Keddache M, Haas JP, Mueller C, Prahalad S, Bohnsack J, Wise CA, Punaro M, Zhang D, Rosé CD, Comeau ME, Divers J, Glass DN, Langefeld CD. The susceptibility loci juvenile idiopathic arthritis shares with other autoimmune diseases extend to PTPN2, COG6, and ANGPT1. Arthritis Rheum. 2010 Nov;62(11):3265-76. doi: 10.1002/art.27688. Barnes MG, Grom AA, Thompson SD, Griffin TA, Luyrink LK, Colbert RA, Glass DN. Biologic similarities based on age at onset in oligoarticular and polyarticular subtypes of juvenile idiopathic arthritis. Arthritis Rheum. 2010 Nov;62(11):3249-58. doi: 10.1002/art.27657. Hinze CH, Fall N, Thornton S, Mo JQ, Aronow BJ, Layh-Schmitt G, Griffin TA, Thompson SD, Colbert RA, Glass DN, Barnes MG, Grom AA. Immature cell populations and an erythropoiesis gene-expression signature in systemic juvenile idiopathic arthritis: implications for pathogenesis. Arthritis Res Ther. 2010;12(3):R123. Thompson SD, Barnes MG, Griffin TA, Grom AA, Glass DN. Heterogeneity in juvenile idiopathic arthritis: impact of molecular profiling based on DNA polymorphism and gene expression patterns. Arthritis Rheum. 2010 Sep;62(9):2611-5. No abstract available. Barnes MG, Grom AA, Thompson SD, Griffin TA, Pavlidis P, Itert L, Fall N, Sowders DP, Hinze CH, Aronow BJ, Luyrink LK, Srivastava S, Ilowite NT, Gottlieb BS, Olson JC, Sherry DD, Glass DN, Colbert RA. Subtype-specific peripheral blood gene expression profiles in recent-onset juvenile idiopathic arthritis. Arthritis Rheum. 2009 Jul;60(7):2102-12. Griffin TA, Barnes MG, Ilowite NT, Olson JC, Sherry DD, Gottlieb BS, Aronow BJ, Pavlidis P, Hinze CH, Thornton S, Thompson SD, Grom AA, Colbert RA, Glass DN. Gene expression signatures in polyarticular juvenile idiopathic arthritis demonstrate disease heterogeneity and offer a molecular classification of disease subsets. Arthritis Rheum. 2009 Jul;60(7):2113-23. Zhang K, Biroschak J, Glass DN, Thompson SD, Finkel T, Passo MH, Binstadt BA, Filipovich A, Grom AA. Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis is associated with MUNC13-4 polymorphisms. Arthritis Rheum. 2008 Sep;58(9):2892-6. Fall N, Barnes M, Thornton S, Luyrink L, Olson J, Ilowite NT, Gottlieb BS, Griffin T, Sherry DD, Thompson S, Glass DN, Colbert RA, Grom AA. Gene expression profiling of peripheral blood from patients with untreated new-onset systemic juvenile idiopathic arthritis reveals molecular heterogeneity that may predict macrophage activation syndrome. Arthritis Rheum. 2007 Nov;56(11):3793-804. Chaudhari M, Moroldo MB, Shear E, Hillard P, Thompson SD, Lan D, Huang B, Brunner HI, Glass DN. Impaired reproductive fitness in mothers of children with juvenile autoimmune arthropathies. Rheumatology (Oxford). 2006 Oct;45(10):1282-7. Phelan JD, Thompson SD, Glass DN. Susceptibility to JRA/JIA: complementing general autoimmune and arthritis traits. Genes Immun. 2006 Jan;7(1):1-10. Review.
Grants
|
Alexei A. Grom, MD
is a pediatric rheumatologist with a special interest in the pathways associated with the development of macrophage activation syndrome, a life-threatening complication of systemic juvenile idiopathic arthritis (SJIA). His work includes a strong translational component; along with studying the mechanisms behind these conditions, his lab is researching potential biomarkers that could facilitate early diagnosis and treatment. Visit the Grom/Thornton Lab.
513-636-3339
alexei.grom@cchmc.org
Alexei A. Grom, MD
Academic Information
Associate Professor, UC Department of Pediatrics
Show All
Specialties
Biography
The research of Alexei Grom, MD, has mainly involved two translational projects focused on two autoimmune diseases – systemic juvenile rheumatoid arthritis and juvenile dermatomyositis. In both projects, recent advances of cellular immunology are applied to these diseases to promote better understanding of their pathogenesis and treatment. Systemic Onset Juvenile Rheumatoid Arthritis and an associated condition known as Macrophage Activation Syndrome are severe and often devastating illnesses. The pathological mechanisms are not known but Dr. Alexei Grom has focused his research on NK and cytotoxic cell function in this disease. The rationale for this approach has been based on the strong clinical similarities between MAS and the better understood autosomal recessive disorder familial hemophagocytic lymphohistiocytosis, in which the uncontrolled proliferation of T cells and macrophages has been recently associated with decreased NK cell and cytotoxic cell functions secondary to mutations in the gene encoding perforin. Recent observations suggest as in FHLH, MAS patients also have profoundly depressed NK function. Moreover, a large subgroup of systemic JRA patients has very similar immunologic abnormalities. Combined with the evidence of the immunoregulatory role of NK cells in many immune responses, this suggests that NK dysfunction is relevant to the pathogenesis of MAS. New directions have thus been established for research in this poorly understood disease. Juvenile Dermatomyositis is a chronic inflammatory condition involving primarily muscles and skin. The most characteristic feature of JDM is vascular damage associated with the capillary necrosis that eventually leads to capillary loss and tissue ischemia. The project is based on the hypothesis that capillary loss in this condition may be caused by angiostatic chemokines that are prominent in the inflammatory response in the affected muscles.
Education and Training
MD: Leningrad (St. Petersburg) Pediatric Medical Institute, Russia, 1986.
Residency: Leningrad (St. Petersburg) Medical Institute, Russia, 1988; Children's Hospital Medical Center, Cincinnati, Ohio, 1998.
Fellowship: Leningrad (St. Petersburg) Pediatric Medical Institute, Russia, 1991; Children's Hospital Medical Center, Cincinnati, Ohio, 1995.
Certification: Pediatrics, 1999.
Publications
View PubMed Publications
Barnes MG, Grom AA, Thompson SD, Griffin TA, Luyrink LK, Colbert RA, Glass DN. Biologic similarities based on age at onset in oligoarticular and polyarticular subtypes of juvenile idiopathic arthritis. Arthritis Rheum. 2010 Nov;62(11):3249-58. Hinze CH, Fall N, Thornton S, Mo JQ, Aronow BJ, Layh-Schmitt G, Griffin TA, Thompson SD, Colbert RA, Glass DN, Barnes MG, Grom AA. Immature cell populations and an erythropoiesis gene-expression signature in systemic juvenile idiopathic arthritis: implications for pathogenesis. Arthritis Res Ther. 2010;12(3):R123. Grom AA, Mellins ED. Macrophage activation syndrome: advances towards understanding pathogenesis. Curr Opin Rheumatol. 2010 Sep;22(5):561-6. Review. Thompson SD, Barnes MG, Griffin TA, Grom AA, Glass DN. Heterogeneity in juvenile idiopathic arthritis: impact of molecular profiling based on DNA polymorphism and gene expression patterns. Arthritis Rheum. 2010 Sep;62(9):2611-5. Filipovich A, McClain K, Grom A. Histiocytic disorders: recent insights into pathophysiology and practical guidelines. Biol Blood Marrow Transplant. 2010 Jan;16(1 Suppl):S82-9. Barnes MG, Grom AA, Thompson SD, Griffin TA, Pavlidis P, Itert L, Fall N, Sowders DP, Hinze CH, Aronow BJ, Luyrink LK, Srivastava S, Ilowite NT, Gottlieb BS, Olson JC, Sherry DD, Glass DN, Colbert RA. Subtype-specific peripheral blood gene expression profiles in recent-onset juvenile idiopathic arthritis. Arthritis Rheum. 2009 Jul;60(7):2102-12. Griffin TA, Barnes MG, Ilowite NT, Olson JC, Sherry DD, Gottlieb BS, Aronow BJ, Pavlidis P, Hinze CH, Thornton S, Thompson SD, Grom AA, Colbert RA, Glass DN. Gene expression signatures in polyarticular juvenile idiopathic arthritis demonstrate disease heterogeneity and offer a molecular classification of disease subsets. Arthritis Rheum. 2009 Jul;60(7):2113-23. Zhang K, Biroschak J, Glass DN, Thompson SD, Finkel T, Passo MH, Binstadt BA, Filipovich A, Grom AA. Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis is associated with MUNC13-4 polymorphisms. Arthritis Rheum. 2008 Sep;58(9):2892-6. Shishov M, Henrickson M, Burgos-Vargas R, Rubio-Pérez N, Baca V, Romero-Feregrino R, Solís-Vallejo E, Huang B, Grom AA, Lovell DJ. Systemic features and early prognostic factors in Hispanic and non-Hispanic children from the United States of America and Mexico with systemic juvenile idiopathic arthritis. Clin Exp Rheumatol. 2007 Nov-Dec;25(6):907-14. Fall N, Barnes M, Thornton S, Luyrink L, Olson J, Ilowite NT, Gottlieb BS, Griffin T, Sherry DD, Thompson S, Glass DN, Colbert RA, Grom AA. Gene expression profiling of peripheral blood from patients with untreated new-onset systemic juvenile idiopathic arthritis reveals molecular heterogeneity that may predict macrophage activation syndrome. Arthritis Rheum. 2007 Nov;56(11):3793-804.
Grants
|
Michael Henrickson, MD, MPH
Clinical Director
focuses on health policy development to improve national pediatric rheumatology workforce capacity. Strategies include creative policy solutions for current workforce challenges, developing telemedicine for pediatric rheumatology outreach to underserved regions, and establishing national benchmarks for clinical productivity. His second research interest is the development of global health initiatives to address the epidemiologic shift in developing countries to chronic conditions, including pediatric rheumatic diseases.
513-636-7686
michael.henrickson@cchmc.org
Michael Henrickson, MD, MPH
Clinical Director
Academic Information
Associate Professor, UC Department of Pediatrics
Show All
Specialties
Health policy; global health; neuropsychiatric-SLE; periodic fever syndromes; systemic JIA; culturally appropriate care; quality measures
Biography
Education and Training
BA: Emory University, Atlanta, GA, 1980.
MD: Jefferson Medical College of Thomas Jefferson University, Philadelphia, PA, 1984.
MPH: College of Public Health, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 2009.
Residency: Tripler Army Medical Center, Honolulu, HI, 1984-87.
Fellowship: Children’s Hospital Medical Center, Cincinnati, OH, 1991-94.
Certification: American Board of Pediatrics: General Pediatrics, 1988 (recertified 2004). Pediatric Rheumatology, 1994 (recertified 2008). National Board of Public Health Examiners, 2009.
Publications
View PubMed Publications
Lovell DJ, Passo MH, Beukelman T, Bowyer SL, Gottlieb BS, Henrickson M, Ilowite NT, Kimura Y, DeWitt EM, Segerman J, Stein LD, Taylor J, Vehe RK, Giannini EH. Measuring process of arthritis care: a proposed set of quality measures for the process of care in juvenile idiopathic arthritis. Arthritis Care Res (Hoboken). 2011 Jan;63(1):10-6. doi: 10.1002/acr.20348. Giannini EH, Ilowite NT, Lovell DJ, Wallace CA, Rabinovich CE, Reiff A, Higgins G, Gottlieb B, Singer NG, Chon Y, Lin SL, Baumgartner SW; Pediatric Rheumatology Collaborative Study Group. Long-term safety and effectiveness of etanercept in children with selected categories of juvenile idiopathic arthritis. Arthritis Rheum. 2009 Sep;60(9):2794-804. Shishov M, Henrickson M, Burgos-Vargas R, Rubio-Pérez N, Baca V, Romero-Feregrino R, Solís-Vallejo E, Huang B, Grom AA, Lovell DJ. Systemic features and early prognostic factors in Hispanic and non-Hispanic children from the United States of America and Mexico with systemic juvenile idiopathic arthritis. Clin Exp Rheumatol. 2007 Nov-Dec;25(6):907-14. Henrickson M, Reid J, Bellet JS, Sawchuk SS, Hirsch R. Comparison of in vivo efficacy and mechanism of action of antimurine monoclonal antibodies directed against TCR alpha beta (H57-597) and CD3 (145-2C11). Transplantation. 1995 Oct 27;60(8):828-35. Henrickson M, Giannini EH, Hirsch R. Reduction of mortality and lymphadenopathy in MRL-lpr/lpr mice treated with nonmitogenic anti-CD3 monoclonal antibody. Arthritis Rheum. 1994 Apr;37(4):587-94.
Grants
|
Daniel J. Lovell, MD, MPH
Associate Director, Division of Rheumatology
focuses on the performance of interventional clinical trials in children with juvenile idiopathic arthritis (JIA) and other rheumatic diseases. He has served as the PI for >30 multicenter, interventional trials in JIA. Dr. Lovell is also involved in the development and validation of outcome measures and clinical response definitions for JIA, JDM and childhood onset systemic lupus erythematosus (SLE).
513-636-4676
daniel.lovell@cchmc.org
Daniel J. Lovell, MD, MPH
Associate Director, Division of Rheumatology
Academic Information
Professor, UC Department of Pediatrics
Show All
Specialties
Clinical InterestsDiagnostic evaluation and ongoing care of children with all pediatric onset rheumatic diseases Research InterestsPerformance of clinical trials in children with rheumatic diseases; clinical trials methodology; mentoring of junior faculty
Biography
Education and Training
MD: University of Kansas, Kansas City, Kan., 1978.
MPH: University of Texas School of Public Health, Houston, Texas, 1982.
Residency: Children's Mercy Hospital, Kansas City, Kan.
Fellowship: Baylor College of Medicine, Houston, Texas.
Certification: Pediatrics, 1984; Pediatric Rheumatology, 1992.
Publications
View PubMed Publications
Lovell DJ, Passo MH, Beukelman T, Bowyer SL, Gottlieb BS, Henrickson M, Ilowite NT, Kimura Y, DeWitt EM, Segerman J, Stein LD, Taylor J, Vehe RK, Giannini EH. Measuring process of arthritis care: a proposed set of quality measures for the process of care in juvenile idiopathic arthritis. Arthritis Care Res (Hoboken). 2011 Jan;63(1):10-6. Giannini EH, Ilowite NT, Lovell DJ, Wallace CA, Rabinovich CE, Reiff A, Higgins G, Gottlieb B, Chon Y, Zhang N, Baumgartner SW. Effects of long-term etanercept treatment on growth in children with selected categories of juvenile idiopathic arthritis.Arthritis Rheum. 2010 Nov;62(11):3259-64. Giannini EH, Ilowite NT, Lovell DJ, Wallace CA, Rabinovich CE, Reiff A, Higgins G, Gottlieb B, Singer NG, Chon Y, Lin SL, Baumgartner SW; Pediatric Rheumatology Collaborative Study Group. Long-term safety and effectiveness of etanercept in children with selected categories of juvenile idiopathic arthritis. Arthritis Rheum. 2009 Sep;60(9):2794-804. Seid M, Opipari L, Huang B, Brunner HI, Lovell DJ. Disease control and health-related quality of life in juvenile idiopathic arthritis. Arthritis Rheum. 2009 Mar 15;61(3):393-9. Carrasco R, Lovell DJ, Giannini EH, Henderson CJ, Huang B, Kramer S, Ranz J, Heubi J, Glass D. Biochemical markers of bone turnover associated with calcium supplementation in children with juvenile rheumatoid arthritis: results of a double-blind, placebo-controlled intervention trial.Arthritis Rheum. 2008 Dec;58(12):3932-40. Lovell DJ, Ruperto N, Goodman S, Reiff A, Jung L, Jarosova K, Nemcova D, Mouy R, Sandborg C, Bohnsack J, Elewaut D, Foeldvari I, Gerloni V, Rovensky J, Minden K, Vehe RK, Weiner LW, Horneff G, Huppertz HI, Olson NY, Medich JR, Carcereri-De-Prati R, McIlraith MJ, Giannini EH, Martini A; Pediatric Rheumatology Collaborative Study Group; Pediatric Rheumatology International Trials Organisation. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med. 2008 Aug 21;359(8):810-20. Ting TV, Lovell DJ. Does early sulfasalazine treatment provide long-term benefits to patients with juvenile idiopathic arthritis?Nat Clin Pract Rheumatol. 2008 Jul;4(7):344-5. Lovell DJ, Reiff A, Ilowite NT, Wallace CA, Chon Y, Lin SL, Baumgartner SW, Giannini EH; Pediatric Rheumatology Collaborative Study Group. Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum. 2008 May;58(5):1496-504. Shishov M, Henrickson M, Burgos-Vargas R, Rubio-Pérez N, Baca V, Romero-Feregrino R, Solís-Vallejo E, Huang B, Grom AA, Lovell DJ. Systemic features and early prognostic factors in Hispanic and non-Hispanic children from the United States of America and Mexico with systemic juvenile idiopathic arthritis. Clin Exp Rheumatol. 2007 Nov-Dec;25(6):907-14. Lovell DJ. Update on treatment of arthritis in children: new treatments, new goals.Bull NYU Hosp Jt Dis. 2006;64(1-2):72-6. Review.
Grants
|
Esi Morgan DeWitt, MD, MSCE
focuses on the development and validation of patient reported outcomes measures using modern psychometric approaches, including item response theory, for improved health assessment in children. A second major research focus concerns improving clinical outcomes of patients with juvenile idiopathic arthritis through the science of quality improvement.
513-636-4676
esi.morgan-dewitt@cchmc.org
Esi Morgan DeWitt, MD, MSCE
Academic Information
Assistant Professor, UC Department of Pediatrics
Show All
Specialties
Clinical InterestsChildhood rheumatic diseases; juvenile idiopathic arthritis; juvenile dermatomyositis; sarcoidosis Research InterestsPatient reported outcomes measure development; quality Improvement; health services research; economic evaluationsl; comparative effectiveness
Biography
Esi Morgan DeWitt, MD, MSCE is a pediatric rheumatologist and researcher. Clinical care spans the childhood rheumatic diseases, with focus on juvenile idiopathic arthritis (JIA) and juvenile dermatomyositis. Her research training and experience includes epidemiology and health services research, in addition to specialization in quality improvement methods and application to improve health care delivery. Dr. Morgan DeWitt leads a research project to develop new measures to assess pain in children and youth, as well as to validate measures of health related quality of life in children with juvenile idiopathic arthritis or chronic pain as part of a national network of investigators. Dr. Morgan DeWitt is a leader in a multi-center quality improvement network to improve the outcome of care in children with JIA, the Pediatric-Rheumatology Care and Outcomes Improvement Network. Additionally, she has served on expert panels in development of JIA treatment recommendations and measures of quality of care in treatment of JIA.
Education and Training
MD: Washington University School of Medicine, St. Louis, MO, 1999. Residency: Pediatrics, Children’s Hospital of Philadelphia, Philadelphia, PA, 2002. Fellowship: Rheumatology, Children’s Hospital of Philadelphia, Philadelphia, PA, 2005. MSCE: University of Pennsylvania, Center for Clinical Epidemiology & Biostatistics, Philadelphia, PA, 2005. Certification: Pediatrics, 2002; Pediatric Rheumatology, 2006.
Publications
View PubMed Publications
Dewitt EM, Stucky BD, Thissen D, Irwin DE, Langer M, Varni JW, Lai JS, Yeatts KB, Dewalt DA. Construction of the eight-item patient-reported outcomes measurement information system pediatric physical function scales: built using item response theory. J Clin Epidemiol. 2011 Jul;64(7):794-804. Beukelman T, Patkar NM, Saag KG, Tolleson-Rinehart S, Cron RQ, DeWitt EM, et al. American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res. 2011 Apr;63(4):465-82. Dinan MA, Compton KL, Dhillon JK, Hammill BG, Dewitt EM, Weinfurt KP, Schulman KA. Use of patient-reported outcomes in randomized, double-blind, placebo-controlled clinical trials. Med Care. 2011 Apr;49(4):415-9. Lovell DJ, Passo MH, Beukelman T, Bowyer SL, Gottlieb BS, Henrickson M, Ilowite NT, Kimura Y, DeWitt EM, Segerman J, Stein LD, Taylor J, Vehe RK, Giannini EH. Measuring process of arthritis care: a proposed set of quality measures for the process of care in juvenile idiopathic arthritis. Arthritis Care Res (Hoboken). 2011 Jan;63(1):10-6. Varni JW, Stucky BD, Thissen D, Dewitt EM, Irwin DE, Lai JS, Yeatts K, Dewalt DA. PROMIS Pediatric Pain Interference Scale: An item response theory analysis of the Pediatric Pain Item Bank. J Pain. 2010 Nov;11(11):1109-19. Irwin DE, Stucky BD, Thissen D, Dewitt EM, Lai JS, Yeatts K, Varni JW, DeWalt DA. Sampling plan and patient characteristics of the PROMIS pediatrics large – scale survey. Qual Life Res. 2010 May;19(4):585-94. DeWitt EM, Lin L, Glick HA, Anstrom KJ, Schulman KA, Reed SD. Pattern and predictors of the initiation of biologic agents for the treatment of rheumatoid arthritis in the United States: an analysis using a large observational data bank. Clin Ther. 2009 Aug; 31(8):1871-80; discussion 1858. Morgan DeWitt E, Glick HA, Albert DA, Joffe M, Wolfe F. Medicare coverage of tumor necrosis factor α inhibitors as an influence on physicians’ prescribing behavior. Arch of Intern Med. 2006;166:57-63. Book Chapters
DeWitt EM, Schanberg LE, Rabinovich CE. Treatment of Rheumatic Diseases. In RM Kleigman, BM Stanton, J St.Geme, N Schor, RE Behrman (Eds.), Nelson Textbook of Pediatrics. 19th ed. Elsevier Saunders: Philadelphia, PA, 2011.
Wu EY, DeWitt, EM. Sarcoidosis. In RM Kleigman, BM Stanton, J St.Geme, N Schor, RE Behrman (Eds.), Nelson Textbook of Pediatrics.19th ed. Elsevier Saunders: Philadelphia, PA, 2011.
Grants
Juvenile Arthritis Improvement Network. Principal Investigator. Arthritis Foundation. July 2010 - Jun 2012. Leveraging Epic for Quality Improvement in Rheumatology. Co-Principal Investigator.Place Outcomes Research Award, Cincinnati Children's Hospital Medical Center. Jul 2010 - Jun 2012. Enhancing PROMIS in Pediatric Pain, Rheumatology and Rehabilitation Research. Principal Investigator. National Institutes of Health. Sep 2009 - Jul 2013. #1U01AR057940-01.
|
Susan Thompson, PhD
leads a translational research program dedicated to identifying juvenile idiopathic arthritis (JIA) genetic risk factors and disease-specific gene expression patterns to help understand the causes of JIA and the mechanisms of disease pathogenesis. This work has the long-term goal of developing molecular definitions of disease that can be used to improve diagnosis and response to therapy in JIA. Visit the Glass/Thompson Lab.
513-636-3899
susan.thompson@cchmc.org
Susan Thompson, PhD
Academic Information
Associate Professor, UC Department of Pediatrics
Show All
Specialties
Molecular basis of juvenile rheumatoid arthritis; large-scale integrative analysis of gene expression, polymorphism and other genomic data with clinical data Visit the Glass-Thompson Lab.
Biography
Susan Thompson, PhD, has research interests that span both genetic and functional genomic studies of juvenile rheumatoid arthritis (JRA) to advance the understanding of the causes and mechanisms of disease pathogenesis. A genome-wide screen for JRA susceptibility traits has been completed and defined several regions for linkage mapping and candidate gene analysis. In addition, complementary approaches that measure global gene expression patterns using DNA microarrays are also being used to understand the molecular basis for disease.
Education and Training
PhD: University of Tennessee Center for Health Sciences, Memphis, TN, 1988.
Fellowship: Immunology, St. Jude Children's Research Hospital, Memphis, TN, 1988-1991.
Fellowship: Molecular Genetics, University of Cincinnati, Cincinnati, OH, 1991-1994.
Publications
View PubMed Publications
Thompson SD, Sudman M, Ramos PS, Marion MC, Ryan M, Tsoras M, Weiler T, Wagner M, Keddache M, Haas JP, Mueller C, Prahalad S, Bohnsack J, Wise CA, Punaro M, Zhang D, Rosé CD, Comeau ME, Divers J, Glass DN, Langefeld CD. The susceptibility loci juvenile idiopathic arthritis shares with other autoimmune diseases extend to PTPN2, COG6, and ANGPT1. Arthritis Rheum. 2010 Nov;62(11):3265-76. Barnes MG, Grom AA, Thompson SD, Griffin TA, Luyrink LK, Colbert RA, Glass DN. Biologic similarities based on age at onset in oligoarticular and polyarticular subtypes of juvenile idiopathic arthritis. Arthritis Rheum. 2010 Nov;62(11):3249-58. Thompson SD, Barnes MG, Griffin TA, Grom AA, Glass DN. Heterogeneity in juvenile idiopathic arthritis: impact of molecular profiling based on DNA polymorphism and gene expression patterns. Arthritis Rheum. 2010 Sep;62(9):2611-5. Hinze CH, Fall N, Thornton S, Mo JQ, Aronow BJ, Layh-Schmitt G, Griffin TA, Thompson SD, Colbert RA, Glass DN, Barnes MG, Grom AA. Immature cell populations and an erythropoiesis gene-expression signature in systemic juvenile idiopathic arthritis: implications for pathogenesis. Arthritis Res Ther. 2010;12(3):R123. Barnes MG, Grom AA, Thompson SD, Griffin TA, Pavlidis P, Itert L, Fall N, Sowders DP, Hinze CH, Aronow BJ, Luyrink LK, Srivastava S, Ilowite NT, Gottlieb BS, Olson JC, Sherry DD, Glass DN, Colbert RA. Subtype-specific peripheral blood gene expression profiles in recent-onset juvenile idiopathic arthritis. Arthritis Rheum. 2009 Jul;60(7):2102-12. Griffin TA, Barnes MG, Ilowite NT, Olson JC, Sherry DD, Gottlieb BS, Aronow BJ, Pavlidis P, Hinze CH, Thornton S, Thompson SD, Grom AA, Colbert RA, Glass DN. Gene expression signatures in polyarticular juvenile idiopathic arthritis demonstrate disease heterogeneity and offer a molecular classification of disease subsets. Arthritis Rheum. 2009 Jul;60(7):2113-23. Zhang K, Biroschak J, Glass DN, Thompson SD, Finkel T, Passo MH, Binstadt BA, Filipovich A, Grom AA. Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis is associated with MUNC13-4 polymorphisms. Arthritis Rheum. 2008 Sep;58(9):2892-6. Chaudhari M, Moroldo MB, Shear E, Hillard P, Thompson SD, Lan D, Huang B, Brunner HI, Glass DN. Impaired reproductive fitness in mothers of children with juvenile autoimmune arthropathies. Rheumatology (Oxford). 2006 Oct;45(10):1282-7. Phelan JD, Thompson SD. Genomic progress in pediatric arthritis: recent work and future goals. Curr Opin Rheumatol. 2006 Sep;18(5):482-9.
Phelan JD, Thompson SD, Glass DN. Susceptibility to JRA/JIA: complementing general autoimmune and arthritis traits. Genes Immun. 2006 Jan;7(1):1-10.
Grants
|
Sherry L. Thornton, PhD
her research focuses on finding and functionally evaluating targets for the treatment of rheumatic disease, with a particular interest in the role of angiogenesis in human arthritis and animal models of arthritis. A second interest is the use of reagents to label inflammatory cells for visualization during arthritis as a potential clinical tool, and for evaluation of cell types during the course of disease in animal models. Visit the Grom/Thornton Lab.
513-636-1318
sherry.thornton@cchmc.org
Sherry L. Thornton, PhD
Academic Information
Assistant Professor, UC Department of Pediatrics
Show All
Specialties
Biography
Education and Training
BS: Ball State University, Muncie, Indiana. PhD: University of Cincinnati, College of Medicine, Cincinnati, OH. Postdoctoral Research Fellow: Cincinnati Children's Hospital Medical Center, Cincinnati, OH.
Publications
View PubMed Publications
Hinze CH, Fall N, Thornton S, Mo JQ, Aronow BJ, Layh-Schmitt G, Griffin TA, Thompson SD, Colbert RA, Glass DN, Barnes MG, Grom AA. Immature cell populations and an erythropoiesis gene-expression signature in systemic juvenile idiopathic arthritis: implications for pathogenesis. Arthritis Res Ther. 2010;12(3):R123.
Griffin TA, Barnes MG, Ilowite NT, Olson JC, Sherry DD, Gottlieb BS, Aronow BJ, Pavlidis P, Hinze CH, Thornton S, Thompson SD, Grom AA, Colbert RA, Glass DN. Gene expression signatures in polyarticular juvenile idiopathic arthritis demonstrate disease heterogeneity and offer a molecular classification of disease subsets. Arthritis Rheum. 2009 Jul;60(7):2113-23.
Fall N, Barnes M, Thornton S, Luyrink L, Olson J, Ilowite NT, Gottlieb BS, Griffin T, Sherry DD, Thompson S, Glass DN, Colbert RA, Grom AA. Gene expression profiling of peripheral blood from patients with untreated new-onset systemic juvenile idiopathic arthritis reveals molecular heterogeneity that may predict macrophage activation syndrome. Arthritis Rheum. 2007 Nov;56(11):3793-804.
Flick MJ, LaJeunesse CM, Talmage KE, Witte DP, Palumbo JS, Pinkerton MD, Thornton S, Degen JL. Fibrin(ogen) exacerbates inflammatory joint disease through a mechanism linked to the integrin alphaMbeta2 binding motif. J Clin Invest. 2007 Nov;117(11):3224-35. Fall N, Bove KE, Stringer K, Lovell DJ, Brunner HI, Weiss J, Higgins GC, Bowyer SL, Graham TB, Thornton S, Grom AA. Association between lack of angiogenic response in muscle tissue and high expression of angiostatic ELR-negative CXC chemokines in patients with juvenile dermatomyositis: possible link to vasculopathy. Arthritis Rheum. 2005 Oct;52(10):3175-80.
Carey B, DeLay M, Strasser JE, Chalk C, Dudley-McClain K, Milligan GN, Brunner HI, Thornton S, Hirsch R. A soluble divalent class I MHC/IgG1 fusion protein activates CD8+ T cells in vivo. Clin Immunol. 2005 Jul;116(1):65-76.
Huang P, Farkas T, Zhong W, Tan M, Thornton S, Morrow AL, Jiang X. Norovirus and histo-blood group antigens: demonstration of a wide spectrum of strain specificities and classification of two major binding groups among multiple binding patterns. J Virol. 2005 Jun;79(11):6714-22.
Hermann LM, Pinkerton M, Jennings K, Yang L, Grom A, Sowders D, Kersten S, Witte DP, Hirsch R, Thornton S. Angiopoietin-like-4 is a potential angiogenic mediator in arthritis. Clin Immunol. 2005 Apr;115(1):93-101. Katakura S, Jennings K, Watanabe S, Adachi E, Thornton S, Gao GP, Wilson JM, Burstein H, Trapnell B, Hirsch R. Recombinant adeno-associated virus preferentially transduces human, compared to mouse, synovium: implications for arthritis therapy. Mod Rheumatol. 2004;14(1):18-24.
Grants
|
Matthew T. Weirauch, PhD
is a computational biologist. His lab is interested in understanding the mechanisms of gene transcriptional regulation. Current projects focus on the characterization of transcription factor binding specificities, and the development of methods for modeling their interactions with DNA, both in vitro and in vivo. His lab also applies insights from basic research on transcription factor-DNA interactions to the study of the mechanisms underlying complex diseases, with particular emphasis on lupus.
513-803-9078
matthew.weirauch@cchmc.org
Matthew T. Weirauch, PhD
Academic Information
Assistant Professor, UC Department of Pediatrics
Show All
Specialties
Transcription factors; transcriptional regulation; functional genomics; genome analysis; network-based algorithms; bioinformatics
Biography
The staggering diversity of life on our planet stems from the elegant system encoded in our genomes. A major finding of the genomic era is that a substantial proportion of the wide range of biological form and function is likely explained by differences in gene regulation (the processes governing how and when genes are utilized), as opposed to differences in the genes themselves. An important component of gene regulation is the binding of transcription factors (TFs) to genomic DNA. A typical metazoan genome contains thousands of TFs, and knowledge of their sequence binding preferences is crucial to our understanding of the “regulatory code” governing health and disease. Two major obstacles stand in our way before we can even begin to accurately model gene regulation. First, we must gain a thorough knowledge of the sequence binding preferences of TFs. Of an estimated 165,000 TFs present in the approximately 300 sequenced eukaryotic organisms, sequence preferences are currently known for only ~2,000 (~1%). In collaboration with Tim Hughes at the University of Toronto, I have developed a joint experimental and computational approach to determine or predict binding preferences for > 55,000 eukaryotic TFs (>30%), representing an order of magnitude improvement over our current knowledge. Second, there is an ongoing controversy surrounding the optimal way to represent TF binding preferences, and how to accurately model them to predict binding to genomic sequences. To address this issue, I have recently led the largest evaluation of computational TF binding models to date, involving 20 methods developed by researchers from around the world. Together, these two studies will provide the groundwork for the future development of models of gene regulation in both normal and disease states.
Education and Training
Postdoctoral Fellow: University of Toronto (Donnelly Center for Cellular and Biomolecular Research), Toronto, Ontario, Canada. PhD: Bioinformatics, University of California Santa Cruz, Santa Cruz, California. BSc: Computer Science, Pennsylvania State University, University Park, PA.
Publications
View PubMed Publications
Weirauch M, Hughes T. A catalogue of eukaryotic transcription factor types, their evolutionary origin, and species distribution. Subcell Biochem. 2011;52:25-73. In: A Handbook of Transcription Factors, First Edition. Springer. Hughes, T, editor. Weirauch M. Gene co-expression networks for the analysis of DNA microarray data. In: Applied Statistics for Network Biology: Methods in Systems Biology, First Edition. Wiley-VCH Verlag. Dehmer M, Emmert-Streib F, Graber A, Salvador A, editors. 2011. Weirauch M, Hughes T. Dramatic changes in transcription factor binding over evolutionary time. Genome Biol. 2010 Jun 1;11(6):122. Wang B, Kline C, Pastor D, Olson T, Frank B, Luu T, Sharma A, Robertson G, Weirauch M, Patierno S, Stuart J, Irby R, Lee N. Prostate apoptosis response protein 4 sensitizes human colon cancer cells to chemotherapeutic 5-FU through mediation of an NF kappaB and microRNA network. Mol Cancer. 2010 Apr 30;9:98. Costanzo M, Baryshnikova A, Bellay J, Kim Y, Spear E, Sevier C, Ding H, Koh J, Toufighi K, Mostafavi S, Prinz J, St Onge R, VanderSluis B, Makhnevych T, Vizeacoumar F, Alizadeh S, Bahr S, Brost R, Chen Y, Cokol M, Deshpande R, Li Z, Lin Z, Liang W, Marback M, Paw J, San Luis B, Shuteriqi E, Tong A, van Dyk N, Wallace I, Whitney J, Weirauch M, Zhong G, Zhu H, Houry W, Brudno M, Ragibizadeh S, Papp B, Pál C, Roth F, Giaever G, Nislow C, Troyanskaya O, Bussey H, Bader G, Gingras A, Morris Q, Kim P, Kaiser C, Myers C, Andrews B, Boone C. The genetic landscape of a cell. Science. 2010 Jan 22;327(5964):425-31. Weirauch M, Hughes T. Conserved expression without conserved regulatory sequence: the more things change, the more they stay the same. Trends Genet. 2010 Feb;26(2):66-74. Weirauch M, Wong C, Byrne A, Stuart J. Information-based methods for predicting gene function from systematic gene knock-downs. BMC Bioinformatics. 2008 Oct 29;9:463. Byrne A, Weirauch M, Wong V, Koeva M, Dixon S, Stuart J, Roy P. A global analysis of genetic interactions in Caenorhabditis elegans. J Biol. 2007;6(3):8. ENCODE Project Consortium. Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. Nature. 2007 Jun 14;447(7146):799-816. Chen C, Weirauch M, Powell C, Zambon A, Stuart J. A search engine to identify new pathway genes from expression data on multiple organisms. BMC Systems Biology. 2007 May 4;1(1):20.
Grants
Lupus Association with Signal Transducer and Activator of Transcription 4. Investigator. US Department of Veterans Affairs. 2012.
|
